Compare ResMed Inc. (RMD) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs ABRDN Physical Gold Shares ETF — how do they compare? ResMed Inc. trades at $194.16 (market cap $28.81B), while ABRDN Physical Gold Shares ETF trades at $38.89. The key difference: ResMed Inc. pays a 1.21% dividend while ABRDN Physical Gold Shares ETF pays none, and ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | SGOL | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $293.73 | $51.41 |
52-Week Low | $182.82 | $31.18 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
SGOL is trading at $38.16, down 0.16% with bearish technical signals dominating. The stock shows 16 sell signals versus only 1 buy signal across technical indicators, with moving averages indicating strong bearish momentum. Recent gold market volatility and interest rate expectations are creating headwinds for gold-related assets. The stock lacks available fundamental data for traditional valuation metrics.
The outlook remains cautious given the bearish technical setup and gold market uncertainty. Investment opportunities exist for contrarian investors betting on gold's safe-haven appeal amid geopolitical tensions. Key risks include continued interest rate pressure, gold price volatility, and the stock's technical weakness potentially extending further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
